Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension
Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomise...
Ausführliche Beschreibung
Autor*in: |
Ambrosioni, Ettore [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2005 |
---|
Schlagwörter: |
---|
Anmerkung: |
© Adis Data Information BV 2005 |
---|
Übergeordnetes Werk: |
Enthalten in: High blood pressure & cardiovascular prevention - [S.l.] : Springer International, 2003, 12(2005), 1 vom: März, Seite 27-35 |
---|---|
Übergeordnetes Werk: |
volume:12 ; year:2005 ; number:1 ; month:03 ; pages:27-35 |
Links: |
---|
DOI / URN: |
10.2165/00151642-200512010-00005 |
---|
Katalog-ID: |
SPR037036386 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR037036386 | ||
003 | DE-627 | ||
005 | 20230519132038.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2005 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2165/00151642-200512010-00005 |2 doi | |
035 | |a (DE-627)SPR037036386 | ||
035 | |a (SPR)00151642-200512010-00005-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ambrosioni, Ettore |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension |
264 | 1 | |c 2005 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Adis Data Information BV 2005 | ||
520 | |a Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. | ||
650 | 4 | |a Metoprolol |7 (dpeaa)DE-He213 | |
650 | 4 | |a Atenolol |7 (dpeaa)DE-He213 | |
650 | 4 | |a Essential Hypertension |7 (dpeaa)DE-He213 | |
650 | 4 | |a Nebivolol |7 (dpeaa)DE-He213 | |
650 | 4 | |a Bisoprolol |7 (dpeaa)DE-He213 | |
700 | 1 | |a Borghi, Claudio |4 aut | |
773 | 0 | 8 | |i Enthalten in |t High blood pressure & cardiovascular prevention |d [S.l.] : Springer International, 2003 |g 12(2005), 1 vom: März, Seite 27-35 |w (DE-627)490226264 |w (DE-600)2192466-1 |x 1179-1985 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2005 |g number:1 |g month:03 |g pages:27-35 |
856 | 4 | 0 | |u https://dx.doi.org/10.2165/00151642-200512010-00005 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_266 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 12 |j 2005 |e 1 |c 03 |h 27-35 |
author_variant |
e a ea c b cb |
---|---|
matchkey_str |
article:11791985:2005----::oeaiiyfeiooihathaciiatilvruohradoeetvbok |
hierarchy_sort_str |
2005 |
publishDate |
2005 |
allfields |
10.2165/00151642-200512010-00005 doi (DE-627)SPR037036386 (SPR)00151642-200512010-00005-e DE-627 ger DE-627 rakwb eng Ambrosioni, Ettore verfasserin aut Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2005 Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. Metoprolol (dpeaa)DE-He213 Atenolol (dpeaa)DE-He213 Essential Hypertension (dpeaa)DE-He213 Nebivolol (dpeaa)DE-He213 Bisoprolol (dpeaa)DE-He213 Borghi, Claudio aut Enthalten in High blood pressure & cardiovascular prevention [S.l.] : Springer International, 2003 12(2005), 1 vom: März, Seite 27-35 (DE-627)490226264 (DE-600)2192466-1 1179-1985 nnns volume:12 year:2005 number:1 month:03 pages:27-35 https://dx.doi.org/10.2165/00151642-200512010-00005 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_266 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2005 1 03 27-35 |
spelling |
10.2165/00151642-200512010-00005 doi (DE-627)SPR037036386 (SPR)00151642-200512010-00005-e DE-627 ger DE-627 rakwb eng Ambrosioni, Ettore verfasserin aut Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2005 Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. Metoprolol (dpeaa)DE-He213 Atenolol (dpeaa)DE-He213 Essential Hypertension (dpeaa)DE-He213 Nebivolol (dpeaa)DE-He213 Bisoprolol (dpeaa)DE-He213 Borghi, Claudio aut Enthalten in High blood pressure & cardiovascular prevention [S.l.] : Springer International, 2003 12(2005), 1 vom: März, Seite 27-35 (DE-627)490226264 (DE-600)2192466-1 1179-1985 nnns volume:12 year:2005 number:1 month:03 pages:27-35 https://dx.doi.org/10.2165/00151642-200512010-00005 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_266 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2005 1 03 27-35 |
allfields_unstemmed |
10.2165/00151642-200512010-00005 doi (DE-627)SPR037036386 (SPR)00151642-200512010-00005-e DE-627 ger DE-627 rakwb eng Ambrosioni, Ettore verfasserin aut Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2005 Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. Metoprolol (dpeaa)DE-He213 Atenolol (dpeaa)DE-He213 Essential Hypertension (dpeaa)DE-He213 Nebivolol (dpeaa)DE-He213 Bisoprolol (dpeaa)DE-He213 Borghi, Claudio aut Enthalten in High blood pressure & cardiovascular prevention [S.l.] : Springer International, 2003 12(2005), 1 vom: März, Seite 27-35 (DE-627)490226264 (DE-600)2192466-1 1179-1985 nnns volume:12 year:2005 number:1 month:03 pages:27-35 https://dx.doi.org/10.2165/00151642-200512010-00005 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_266 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2005 1 03 27-35 |
allfieldsGer |
10.2165/00151642-200512010-00005 doi (DE-627)SPR037036386 (SPR)00151642-200512010-00005-e DE-627 ger DE-627 rakwb eng Ambrosioni, Ettore verfasserin aut Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2005 Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. Metoprolol (dpeaa)DE-He213 Atenolol (dpeaa)DE-He213 Essential Hypertension (dpeaa)DE-He213 Nebivolol (dpeaa)DE-He213 Bisoprolol (dpeaa)DE-He213 Borghi, Claudio aut Enthalten in High blood pressure & cardiovascular prevention [S.l.] : Springer International, 2003 12(2005), 1 vom: März, Seite 27-35 (DE-627)490226264 (DE-600)2192466-1 1179-1985 nnns volume:12 year:2005 number:1 month:03 pages:27-35 https://dx.doi.org/10.2165/00151642-200512010-00005 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_266 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2005 1 03 27-35 |
allfieldsSound |
10.2165/00151642-200512010-00005 doi (DE-627)SPR037036386 (SPR)00151642-200512010-00005-e DE-627 ger DE-627 rakwb eng Ambrosioni, Ettore verfasserin aut Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis Data Information BV 2005 Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. Metoprolol (dpeaa)DE-He213 Atenolol (dpeaa)DE-He213 Essential Hypertension (dpeaa)DE-He213 Nebivolol (dpeaa)DE-He213 Bisoprolol (dpeaa)DE-He213 Borghi, Claudio aut Enthalten in High blood pressure & cardiovascular prevention [S.l.] : Springer International, 2003 12(2005), 1 vom: März, Seite 27-35 (DE-627)490226264 (DE-600)2192466-1 1179-1985 nnns volume:12 year:2005 number:1 month:03 pages:27-35 https://dx.doi.org/10.2165/00151642-200512010-00005 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_266 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2005 1 03 27-35 |
language |
English |
source |
Enthalten in High blood pressure & cardiovascular prevention 12(2005), 1 vom: März, Seite 27-35 volume:12 year:2005 number:1 month:03 pages:27-35 |
sourceStr |
Enthalten in High blood pressure & cardiovascular prevention 12(2005), 1 vom: März, Seite 27-35 volume:12 year:2005 number:1 month:03 pages:27-35 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Metoprolol Atenolol Essential Hypertension Nebivolol Bisoprolol |
isfreeaccess_bool |
false |
container_title |
High blood pressure & cardiovascular prevention |
authorswithroles_txt_mv |
Ambrosioni, Ettore @@aut@@ Borghi, Claudio @@aut@@ |
publishDateDaySort_date |
2005-03-01T00:00:00Z |
hierarchy_top_id |
490226264 |
id |
SPR037036386 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR037036386</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519132038.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2005 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00151642-200512010-00005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR037036386</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00151642-200512010-00005-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ambrosioni, Ettore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis Data Information BV 2005</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metoprolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atenolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Essential Hypertension</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nebivolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bisoprolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borghi, Claudio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">High blood pressure & cardiovascular prevention</subfield><subfield code="d">[S.l.] : Springer International, 2003</subfield><subfield code="g">12(2005), 1 vom: März, Seite 27-35</subfield><subfield code="w">(DE-627)490226264</subfield><subfield code="w">(DE-600)2192466-1</subfield><subfield code="x">1179-1985</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:1</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:27-35</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00151642-200512010-00005</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_266</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2005</subfield><subfield code="e">1</subfield><subfield code="c">03</subfield><subfield code="h">27-35</subfield></datafield></record></collection>
|
author |
Ambrosioni, Ettore |
spellingShingle |
Ambrosioni, Ettore misc Metoprolol misc Atenolol misc Essential Hypertension misc Nebivolol misc Bisoprolol Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension |
authorStr |
Ambrosioni, Ettore |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)490226264 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1179-1985 |
topic_title |
Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension Metoprolol (dpeaa)DE-He213 Atenolol (dpeaa)DE-He213 Essential Hypertension (dpeaa)DE-He213 Nebivolol (dpeaa)DE-He213 Bisoprolol (dpeaa)DE-He213 |
topic |
misc Metoprolol misc Atenolol misc Essential Hypertension misc Nebivolol misc Bisoprolol |
topic_unstemmed |
misc Metoprolol misc Atenolol misc Essential Hypertension misc Nebivolol misc Bisoprolol |
topic_browse |
misc Metoprolol misc Atenolol misc Essential Hypertension misc Nebivolol misc Bisoprolol |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
High blood pressure & cardiovascular prevention |
hierarchy_parent_id |
490226264 |
hierarchy_top_title |
High blood pressure & cardiovascular prevention |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)490226264 (DE-600)2192466-1 |
title |
Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension |
ctrlnum |
(DE-627)SPR037036386 (SPR)00151642-200512010-00005-e |
title_full |
Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension |
author_sort |
Ambrosioni, Ettore |
journal |
High blood pressure & cardiovascular prevention |
journalStr |
High blood pressure & cardiovascular prevention |
lang_code |
eng |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2005 |
contenttype_str_mv |
txt |
container_start_page |
27 |
author_browse |
Ambrosioni, Ettore Borghi, Claudio |
container_volume |
12 |
format_se |
Elektronische Aufsätze |
author-letter |
Ambrosioni, Ettore |
doi_str_mv |
10.2165/00151642-200512010-00005 |
title_sort |
tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension |
title_auth |
Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension |
abstract |
Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. © Adis Data Information BV 2005 |
abstractGer |
Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. © Adis Data Information BV 2005 |
abstract_unstemmed |
Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance. © Adis Data Information BV 2005 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_266 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension |
url |
https://dx.doi.org/10.2165/00151642-200512010-00005 |
remote_bool |
true |
author2 |
Borghi, Claudio |
author2Str |
Borghi, Claudio |
ppnlink |
490226264 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.2165/00151642-200512010-00005 |
up_date |
2024-07-03T20:50:46.274Z |
_version_ |
1803592501847654400 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR037036386</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519132038.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2005 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00151642-200512010-00005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR037036386</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00151642-200512010-00005-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ambrosioni, Ettore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis Data Information BV 2005</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database searches of MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to August 2004 identified randomised clinical trials comparing nebivolol and other CSBs in patients with mild-to-moderate hypertension, with a treatment duration of at least 4 weeks and reporting any tolerability data. Design and methods: Baseline and post-intervention data on tolerability and efficacy were extracted from the studies. Tolerability was assessed by the rate of patients with adverse events (AEs), the total number of AEs and the number of drug-related AEs. Efficacy endpoints were the changes from baseline in diastolic and systolic blood pressure and the rate of treatment responders. For meta-analysis of data presenting relative frequency or means and standard deviations, the random effects model for proportions and means was applied. Absolute frequency data were normalised to the expected frequencies in 1000 patients and analysed by methods for comparison of Poisson distributed data. The quality of each trial was evaluated using a pre-defined checklist reflecting the basic potency of a selected study to detect the relative tolerability of the drugs investigated. The final analysis was performed in the high-quality studies; the low-quality studies were included, where appropriate, in robustness analysis. Results: Ten trials comparing nebivolol with the CSBs atenolol, metoprolol or bisoprolol were selected. According to the pre-defined criteria, three studies were assessed as high-quality studies and seven as low-quality studies. The ratio of the rates of patients with AEs treated with nebivolol compared with those treated with the CSBs was 0.63 (95% CI 0.44, 0.91). The difference of the rates of patients with AEs reached −12.8% (95% CI −23.3%, −2.3%). The ratio of normalised total AEs was 0.71 (95% CI 0.62, 0.82), and the ratio of normalised drug-related AEs was 0.38 (95% CI 0.29, 0.50). In the expected frequencies of AEs in 1000 patients, the differences in number of normalised total AEs and drug-related AEs with nebivolol compared with the other CSBs were −147 (95% CI −205, −89) and −126 (95% CI −159, −93), respectively. In the efficacy meta-analysis, nebivolol was at least as effective as the other CSBs. Conclusions: This meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprolol, and confirmed that nebivolol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. The treatment of mild-to-moderate essential hypertension with antihypertensive drugs that have a relatively favourable tolerability profile, such as nebivolol, may be a way to improve persistence with antihypertensive treatment and overcome the consequences of poor compliance.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metoprolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atenolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Essential Hypertension</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nebivolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bisoprolol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borghi, Claudio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">High blood pressure & cardiovascular prevention</subfield><subfield code="d">[S.l.] : Springer International, 2003</subfield><subfield code="g">12(2005), 1 vom: März, Seite 27-35</subfield><subfield code="w">(DE-627)490226264</subfield><subfield code="w">(DE-600)2192466-1</subfield><subfield code="x">1179-1985</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:1</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:27-35</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00151642-200512010-00005</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_266</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2005</subfield><subfield code="e">1</subfield><subfield code="c">03</subfield><subfield code="h">27-35</subfield></datafield></record></collection>
|
score |
7.3983355 |